Biogen soars 64% after FDA approves first new Alzheimer's drug in 18 years
The FDA approval marks the first treatment cleared by US regulators to decelerate cognitive decline in people with Alzheimer's.
Full Article
Biogen soars 64% after FDA approves first new Alzheimer's drug in 18 years
Business Insider
0 shares
1 views
You might like
Related news coverage
Nvidia & darpa biohybrid
Rumble
https://www.youtube.com/watch?v=0Hg7XhbXuac . No One is Talking About What Just Happened..
-
What universal healthcare should look like
Mashable
-
Q BioMed has a winner in cancer bone pain drug Strontium89 and a deep pipeline of biomedical assets
Proactive Investors
-
Kazia Therapeutics makes strong progress with clinical programs for paxalisib and EVT801
Proactive Investors
-
S&P/ASX 200 gains 0.63%; Telstra sells towers business for $2.8 billion
Proactive Investors
Advertisement
More coverage
PureTech Health provides the blue-print for value creation in the life sciences sector
Proactive Investors
Spotting the weakness of a potential treatment early in the R&D process can save hundreds of millions of dollars that can be..
-
Lilly to seek FDA approval for potential Alzheimer's drug
SeattlePI.com
-
How the new Alzheimer’s disease drug could influence future research
Upworthy
-
NA Proactive news snapshot: Progressive Planet, Real Luck Group, Deep-South Resources, Kidoz, Sigma Lithium UPDATE …
Proactive Investors
-
Stocks end mixed but Nasdaq powers to another record close
Proactive Investors